These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 18390538

  • 1. Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy.
    Skurk C, Wittchen F, Suckau L, Witt H, Noutsias M, Fechner H, Schultheiss HP, Poller W.
    Eur Heart J; 2008 May; 29(9):1168-80. PubMed ID: 18390538
    [Abstract] [Full Text] [Related]

  • 2. Programmed cell death in idiopathic dilated cardiomyopathy is mediated by suppression of the apoptosis inhibitor Apollon.
    Aharinejad S, Andrukhova O, Lucas T, Zuckermann A, Wieselthaler G, Wolner E, Grimm M.
    Ann Thorac Surg; 2008 Jul; 86(1):109-14; discussion 114. PubMed ID: 18573408
    [Abstract] [Full Text] [Related]

  • 3. Impaired VE-cadherin/beta-catenin expression mediates endothelial cell degeneration in dilated cardiomyopathy.
    Schäfer R, Abraham D, Paulus P, Blumer R, Grimm M, Wojta J, Aharinejad S.
    Circulation; 2003 Sep 30; 108(13):1585-91. PubMed ID: 12963640
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Adiponectin expression in patients with inflammatory cardiomyopathy indicates favourable outcome and inflammation control.
    Bobbert P, Scheibenbogen C, Jenke A, Kania G, Wilk S, Krohn S, Stehr J, Kuehl U, Rauch U, Eriksson U, Schultheiss HP, Poller W, Skurk C.
    Eur Heart J; 2011 May 30; 32(9):1134-47. PubMed ID: 21278397
    [Abstract] [Full Text] [Related]

  • 6. Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy.
    Vanderheyden M, Paulus WJ, Voss M, Knuefermann P, Sivasubramanian N, Mann D, Baumgarten G.
    Heart; 2005 Jul 30; 91(7):926-31. PubMed ID: 15958363
    [Abstract] [Full Text] [Related]

  • 7. Monocyte chemoattractant protein 1 (MCP-1) gene expression in dilated cardiomyopathy.
    Lehmann MH, Kühnert H, Müller S, Sigusch HH.
    Cytokine; 1998 Oct 30; 10(10):739-46. PubMed ID: 9811526
    [Abstract] [Full Text] [Related]

  • 8. Isoform-specific downregulation of peroxiredoxin in human failing myocardium.
    Brixius K, Schwinger RH, Hoyer F, Napp A, Renner R, Bölck B, Kümin A, Fischer U, Mehlhorn U, Werner S, Bloch W.
    Life Sci; 2007 Aug 16; 81(10):823-31. PubMed ID: 17727896
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Regional heterogeneity of decreased myocardial norepinephrine and increased lipid peroxidation levels in patients with end-stage failing heart secondary to dilated or ischemic cardiomyopathy.
    Rochette L, Tatou E, Vergely C, Maupoil V, Bouchot O, Mossiat C, Jazayeri S, Benkhadra S, Brenot R, Girard C, David M.
    J Heart Lung Transplant; 2008 Jul 16; 27(7):767-74. PubMed ID: 18582807
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Humoral anti-proteasomal autoimmunity in dilated cardiomyopathy.
    Voigt A, Bartel K, Egerer K, Trimpert C, Feist E, Gericke C, Kandolf R, Klingel K, Kuckelkorn U, Stangl K, Felix SB, Baumann G, Kloetzel PM, Staudt A.
    Basic Res Cardiol; 2010 Jan 16; 105(1):9-18. PubMed ID: 19760349
    [Abstract] [Full Text] [Related]

  • 13. Comparative study of the roles of cytokines and apoptosis in dilated and hypertrophic cardiomyopathies.
    Buzás K, Megyeri K, Hõgye M, Csanády M, Bogáts G, Mándi Y.
    Eur Cytokine Netw; 2004 Jan 16; 15(1):53-9. PubMed ID: 15217753
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy.
    Francis SE, Holden H, Holt CM, Duff GW.
    J Mol Cell Cardiol; 1998 Feb 16; 30(2):215-23. PubMed ID: 9514998
    [Abstract] [Full Text] [Related]

  • 15. Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies.
    Barth AS, Kuner R, Buness A, Ruschhaupt M, Merk S, Zwermann L, Kääb S, Kreuzer E, Steinbeck G, Mansmann U, Poustka A, Nabauer M, Sültmann H.
    J Am Coll Cardiol; 2006 Oct 17; 48(8):1610-7. PubMed ID: 17045896
    [Abstract] [Full Text] [Related]

  • 16. Significance of dyslipidaemia in patients with heart failure of unexplained aetiology.
    Skwarek M, Bilińska ZT, Mazurkiewicz Ł, Grzybowski J, Kruk M, Kurjata P, Piotrowski W, Ruzyłło W.
    Kardiol Pol; 2008 May 17; 66(5):515-22, discussion 523-4. PubMed ID: 18537059
    [Abstract] [Full Text] [Related]

  • 17. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function.
    Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Bellocci F, Crea F, Maseri A.
    Eur Heart J; 2007 May 17; 28(9):1117-27. PubMed ID: 17389654
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. MicroRNA-150 inhibits expression of adiponectin receptor 2 and is a potential therapeutic target in patients with chronic heart failure.
    Kreth S, Ledderose C, Schütz S, Beiras A, Heyn J, Weis F, Beiras-Fernandez A.
    J Heart Lung Transplant; 2014 Mar 17; 33(3):252-60. PubMed ID: 24239242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.